Glenmark Pharma Shares Jump 14%, Analysts Set ₹2,800 Target
Glenmark Pharma surged 14% after announcing an AbbVie-linked licensing deal. Analysts raised their price targets to ₹2,800, citing technical momentum and continued upside potential of nearly 29%. Source Image: economictimes...
